Clinicogenomic Characteristics and Treatment Outcomes of Patients With Advanced ALK -Rearranged Squamous and Adenosquamous Non–Small Cell Lung Cancers

Read full text Summarise with VIRAT
Authors: Emily A. Miao, Beow Yong Yeap, Sameh Daher, Meghanne Lomibao, Fangdi Sun, Rachel J. Keogh, Jason P. Lambden, Amanda Reyes, Jennifer L. Peterson, Joyce H. Liang, Audrey Liu, Andrew Do
+11 more Carrie Lee, Melinda Laine Hsu, Makenzi Colleen Evangelist, Joshua E. Reuss, Shirish M. Gadgeel, Matthew Lee, Tejas Patil, Vincent K. L. Lam, Joel W. Neal, A. Drilon, Jessica J. Lin
Cited by: 0
References: 40

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

PURPOSE Anaplastic lymphoma kinase (ALK) is an established therapeutic target in non–small cell lung cancer (NSCLC), predominantly identified in adenocarcinomas. However, ALK rearrangements also occur in de novo squamous and adenosquamous NSCLCs and their clinicogenomic features remain poorly defined. METHODS This multi-institutional retrospective analysis included patients with advanced ALK+ NSCLC. Patients with de novo ALK+ squamous and adenosquamous NSCLCs were identified and compared with an ALK+ adenocarcinoma cohort treated with first-line (1L) alectinib. Overall survival (OS), time to progression (TTP), and time to treatment discontinuation (TTD) were analyzed using the Kaplan-Meier methodology. RESULTS Among 177 patients, 29 had ALK+ squamous (n = 17) and adenosquamous (n = 12) NSCLCs and 148 had ALK+ adenocarcinoma treated with 1L alectinib. Among patients receiving 1L alectinib, OS was significantly shorter for patients with adenosquamous (median, 31.0 months [95% CI, 17.0 to not reached {NR}]) and squamous (27.0 months [95% CI, 5.0 to 35.0]) tumors compared with that for patients with adenocarcinoma (median NR; median follow-up 51.2 months; P < .001). TTP was shorter for squamous (median, 8.0 months [95% CI, 2.0 to 12.0]) versus adenocarcinoma (median, 19.0 months [95% CI, 12.6 to 25.0]) cohorts ( P < .001), although the adenosquamous cohort had comparable TTP (median, 20.0 months [95% CI, 9.4 to 30.6]) with the adenocarcinoma cohort ( P = .70). TTD was significantly shorter for squamous (median, 9.5 months [95% CI, 1.5 to 13.0]) and adenosquamous (median, 20.0 months [95% CI, 3.0 to 24.0]) versus adenocarcinoma cohorts (52.3 months [95% CI, 40.5 to 57.5]; P < .001). Genomic profiling revealed more frequent TP53 (53% v 25%; P = .026), PDGFRA (16% v 0%; P = .009), KIT (11% v 0%; P = .045), PIK3CA (11% v 0%; P = .045), and MYC (11% v 0%; P = .045) coalterations in the squamous/adenosquamous cohort. CONCLUSION ALK+ squamous and adenosquamous NSCLCs are rare, but biologically distinct, with inferior outcomes on 1L ALK TKI, highlighting the need for further research to develop effective treatment strategies.

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Lung Cancer Research Studies Lung Cancer Diagnosis and Treatment

Publication details

Journal / source
JCO Precision Oncology
Volume
10
Issue
3
Pages
e2501148–e2501148
Publication date
1 March 2026
Language
EN